Further clinical trial planned for Valneva’s COVID-19 vaccine candidate
Valneva is planning to initiate a further Phase III trial (VLA2001-304) for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
The new VLA2001-304 s...
Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.
Continue readingExploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.
Continue readingExploring emerging approaches to neurodegenerative disease research and treatment.
Continue readingHighlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
Advertisement